266 related articles for article (PubMed ID: 33359014)
1. Incidence and disease burden of herpes zoster in the population aged ≥50 years in China: Data from an integrated health care network.
Sun X; Wei Z; Lin H; Jit M; Li Z; Fu C
J Infect; 2021 Feb; 82(2):253-260. PubMed ID: 33359014
[TBL] [Abstract][Full Text] [Related]
2. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E
J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.
Gialloreti LE; Merito M; Pezzotti P; Naldi L; Gatti A; Beillat M; Serradell L; di Marzo R; Volpi A
BMC Infect Dis; 2010 Aug; 10():230. PubMed ID: 20682044
[TBL] [Abstract][Full Text] [Related]
4. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia.
Friesen KJ; Chateau D; Falk J; Alessi-Severini S; Bugden S
BMC Infect Dis; 2017 Jan; 17(1):69. PubMed ID: 28086817
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden of Herpes Zoster ("culebrilla") in Latin America.
Rampakakis E; Pollock C; Vujacich C; Toniolo Neto J; Ortiz Covarrubias A; Monsanto H; Johnson KD
Int J Infect Dis; 2017 May; 58():22-26. PubMed ID: 28267595
[TBL] [Abstract][Full Text] [Related]
6. Incidence of herpes zoster and post-herpetic neuralgia in Italy: Results from a 3-years population-based study.
Alicino C; Trucchi C; Paganino C; Barberis I; Boccalini S; Martinelli D; Pellizzari B; Bechini A; Orsi A; Bonanni P; Prato R; Iannazzo S; Icardi G
Hum Vaccin Immunother; 2017 Feb; 13(2):399-404. PubMed ID: 27925843
[TBL] [Abstract][Full Text] [Related]
7. Increasing incidence associated with herpes zoster infection in British Columbia, Canada.
Marra F; Chong M; Najafzadeh M
BMC Infect Dis; 2016 Oct; 16(1):589. PubMed ID: 27765026
[TBL] [Abstract][Full Text] [Related]
8. Herpes zoster and postherpetic neuralgia in Catalonia (Spain).
Salleras L; Salleras M; Salvador P; Soldevila N; Prat A; Garrido P; Domínguez A
Hum Vaccin Immunother; 2015; 11(1):178-84. PubMed ID: 25483532
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom.
Gauthier A; Breuer J; Carrington D; Martin M; Rémy V
Epidemiol Infect; 2009 Jan; 137(1):38-47. PubMed ID: 18466661
[TBL] [Abstract][Full Text] [Related]
10. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009-2014.
Muñoz-Quiles C; López-Lacort M; Díez-Domingo J; Orrico-Sánchez A
BMC Infect Dis; 2020 Nov; 20(1):905. PubMed ID: 33256624
[TBL] [Abstract][Full Text] [Related]
11. Burden of disease from shingles and post-herpetic neuralgia in the over 80 year olds in the UK.
Matthews I; Duong M; Parsons VL; Nozad B; Qizilbash N; Patel Y; Guimicheva B
PLoS One; 2020; 15(2):e0229224. PubMed ID: 32097441
[TBL] [Abstract][Full Text] [Related]
12. A population based study of the epidemiology of Herpes Zoster and its complications.
Weitzman D; Shavit O; Stein M; Cohen R; Chodick G; Shalev V
J Infect; 2013 Nov; 67(5):463-9. PubMed ID: 23872209
[TBL] [Abstract][Full Text] [Related]
13. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.
White RR; Lenhart G; Singhal PK; Insinga RP; Itzler RF; Pellissier JM; Segraves AW
Pharmacoeconomics; 2009; 27(9):781-92. PubMed ID: 19757871
[TBL] [Abstract][Full Text] [Related]
14. Vaccination: a new option to reduce the burden of herpes zoster.
Mick G
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
[TBL] [Abstract][Full Text] [Related]
15. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis.
Curran D; Hunjan M; El Ghachi A; El-Hahi Y; Bianco V; Ferreira G
BMJ Open; 2019 Aug; 9(8):e023502. PubMed ID: 31462457
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
17. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
[TBL] [Abstract][Full Text] [Related]
18. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012.
Yanni EA; Ferreira G; Guennec M; El Hahi Y; El Ghachi A; Haguinet F; Espie E; Bianco V
BMJ Open; 2018 Jun; 8(6):e020528. PubMed ID: 29880565
[TBL] [Abstract][Full Text] [Related]
19. A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China.
Lu L; Suo L; Li J; Pang X
Hum Vaccin Immunother; 2018; 14(11):2632-2635. PubMed ID: 30059639
[TBL] [Abstract][Full Text] [Related]
20. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction.
Yawn BP; Saddier P; Wollan PC; St Sauver JL; Kurland MJ; Sy LS
Mayo Clin Proc; 2007 Nov; 82(11):1341-9. PubMed ID: 17976353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]